| Summary: | 碩士 === 國立臺灣大學 === 應用力學研究所 === 99 === There are many different kinds of anticancer drugs for chemotherapy nowadays. The most important issue to doctors is the choice of anticancer drug for specific patients. Once patients were treated with ineffective treatment, the patients would need further repeats of chemotherapy which was really harmful to patients.
In order to solve the problem stated above, we present a microfluidic device to conduct chemosensitivity microfluidic assay (CheMA) for primary cell-based individualized chemosensitivity profiling while consuming 9,000 cells for single reagent response assay. Cancer cells from patients were seeded into microfluidic device and treated with 3 concentrations of 2 major used anticancer drugs. Roughly, only 9,000 cells in total were required for a single drug response assay by CheMA. In addition, cells in units of microfluidic device were conserved by conducting solution exchange through surrounding microchannels. After drug treatment, cell viability was quantified by a tri-staining method to distinguish cancer cells, normal cells and dead cells. MCF7 and MDA-MB-231 cell lines were applied to anticancer drug screening to prove the feasibility of drug response assay by CheMA.
No statistical significance was found in dose-responses between CheMA and 96-well plate controls. Furthermore, the IC50 values of cisplatin and docetaxel were similar between the two platforms. Moreover, the drug response of patient samples were conducted by CheMA with few cells demanded. Primary samples of breast cancer patients were also examined by CheMA.
In short, CheMA could be applied to prediction of individual chemotherapy within days when the sizes of tumors were not enough for a complete traditional assay.
|
|---|
